CRISPR Therapeutics AG
CRSPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, CRISPR Therapeutics AG focuses on Biotechnology services and products. CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats. With a market capitalization of $5.39B, it sits in mid-cap territory. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Market Cap
$5.39B
Beta
1.76
P/E (TTM)
—
P/E (Fwd)
-15.95
EPS (TTM)
$-4.71
EPS (Fwd)
$-3.50
ROE
-26.1%
ROA
-14.2%
Cash
$2.36B
Total Debt
$783.7M
Free CF
-$215.8M
52W Change
3.9%
Annual Financials
Cash vs Debt
Where CRSP stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CRSP finished 8.11% above its 150-day moving average ($52.65) and 6.95% above its 200-day moving average ($53.22). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRSP overbought or oversold?
At the September 3, 2026 close, CRSP's RSI(14) was 56.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $2.36B in cash and $783.7M in debt, CRSP maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$215.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -26.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $436K (2022) to $0 (2025), a 100% decline worth watching.
A beta of 1.76 means CRSP is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence CRISPR Therapeutics AG's trajectory.